Atrial fibrillation, a condition whose symptoms are irregular and/or rapid heartbeats, affected an estimated 33.5 mn individuals worldwide as of 2010. The World Health Organization (WHO) has termed the condition as a “growing global health concern”.According to the estimations of TMR’s study, the market is expected to rise at a compounded annual growth rate (CAGR) of 13.4% between 2013 and 2019. The report further states that the market stood at a valuation of US$6.1 bn in 2012 and will touch US$14.8 bn by 2019.
Get Free Sample Report Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1541
As the risk of atrial fibrillation increases with age, the growing number of aged individuals worldwide will generate a greater demand for atrial fibrillation devices and treatments, says TMR’s report. Moreover, TMR analysts reckon that the growing prevalence of chronic disorders, including hypertension and diabetes, will lead to a growth in the number of people suffering from atrial fibrillation. All of these factors will put the global atrial fibrillation market firmly on the growth course. However, companies in the global atrial fibrillation market will have to brave headwinds in the form of strict approval processes before a treatment or product can be brought to the market and close monitoring of the market by regulatory agencies.
The report on the global atrial fibrillation market segments the market on the basis of type into: pharmacological treatment and non-pharmacological treatment. The pharmacological treatment segment is sub-segmented into anti-arrhythmic drugs and anti-coagulant drugs. Likewise, the non-pharmacological treatment market has been divided into: maze surgery, catheter ablation, and electric cardioversion.
The global market for atrial fibrillation was dominated by the pharmacological treatment segment as of 2012. There are several reasons that support the estimations that this segment held the largest share in the atrial fibrillation market in that year.
The key reason is that drugs are more frequently consumed by patients suffering from AF while fewer patients undergo non-pharmacological treatments. Even in instances where patients undergo non-pharmacological intervention to treat AF, pharmacological treatments are administered during convalescence or as a follow-up. It is also important to consider the point that pharmacological treatments are more affordable than non-pharmacological ones. The report states that by 2019, the share of pharmacological treatments in the global atrial fibrillation market will rise to approximately 55% boosted by the launch of new anti-coagulants
On the basis of geography, the key segments of the market are: Europe, North America, Asia Pacific, and the Rest of the World. Of these, North America stood as the largest region in 2012 in terms of both sales revenue and volume. The fastest growth rate will be seen in the Asia Pacific atrial fibrillation market, the report further states.
AtriCure, Inc., Biosense Webster, Inc., CardioFocus, Inc., Boston Scientific Corporation, and St. Jude Medical, Inc. are among the key players reviewed in the report.
Access Full Report: http://www.transparencymarketresearch.com/atrial-fibrillation-market.html
The global atrial fibrillation market is categorized into the following segments:
Atrial Fibrillation Market, by Treatment Types
- Pharmacological Treatment
- Anti-Arrhythmic Drugs
- Anti-Coagulant Drugs
- Catheter Ablation
- Radiofrequency Based
- Cryoablation Based
- HIFU (High Intensity Focused Ultrasound) Based
- Microwave Based
- Laser Based
- Maze Surgery
- Electric Cardioversion
Atrial Fibrillation Market, by Geography
- North America
- Rest of the World (RoW)